Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 18Sarcoma 15Burkitt Lymphoma 9Breast Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasm Metastasis 8Triple Negative Breast Neoplasms 7Lymphoma, T-Cell, Peripheral 7Lymphoma, Follicular 7Lymphoma, B-Cell 7Ovarian Neoplasms 6Lymphoma 6Hodgkin Disease 6Endometrial Neoplasms 5Osteosarcoma 4Neuroblastoma 4Lymphoma, Non-Hodgkin 4Liposarcoma 4Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Peritoneal Neoplasms 3Neoplasms 3Leukemia, Biphenotypic, Acute 3Leiomyosarcoma 3Histiocytoma, Malignant Fibrous 3Hemangiosarcoma 3Colorectal Neoplasms 3Uterine Neoplasms 2Stomach Neoplasms 2Sarcoma, Synovial 2

Interventions

Injections 6Fluorodeoxyglucose F18 4Cyclophosphamide 4Bevacizumab 4toripalimab 3fludarabine 2Specimen Handling 2Nivolumab 2zimberelimab 1tumor-cells apoptosis factor, human 1trametinib 1tislelizumab 1temsirolimus 1spartalizumab 1pembrolizumab 1pazopanib 1palbociclib 1olaparib 1lenvatinib 1etoposide phosphate 1enzalutamide 1envafolimab 1donafenib 1disitamab vedotin 1dabrafenib 1cemiplimab 1avelumab 1atezolizumab 1anlotinib 1WW Domain-Containing Oxidoreductase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Solid Tumor × Doxorubicin × Clear all
NCT05661201 2026-03-06

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Georgetown University

Phase 1 Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡